Myalgic Encephalomyelitis (ME) affects millions of European citizens and their families and brings an enormous
financial burden to European economies. Yet little attention and insignificant funding is provided for research into this disease or
for services for patients.
The European ME Research collaboration brings together the complementary abilities in clinical expertise, research
and advocacy that are available from three European organisations who are working to improve the future for people affected by
myalgic encephalomyelitis (ME) in Europe.
ME IN NUMBERS
Europeans estimated to be affected by ME - at least
Above are all estimated as no official figures have ever been taken
European ME Clinicians Council is a network of clinicians treating ME patients and working together to share expertise, produce and maintain up-to-date diagnostic methods and assist researchers in building research into this disease.
European ME Clinicians CouncilLEARN MORE
The European ME Research Group (EMERG) is a network of European ME researchers who formed to collaborate and share knowledge in research into myalgic encephalomyeltis (ME)
European ME Research Group
EMEA is a grouping of European organisations who are involved in supporting patients suffering from ME and are campaigning for funding for biomedical research to provide treatments and cures for ME
European ME Alliance
Bringing together three European organisations all working towards the same objectives
Europe and ME
Europe has the means to resolve ME. By using the best knowledge, expertise and facilities Europe can discover the cause(s) and develop treatment(s) forthis condition.
European Biomedical Research
EMERG has been established to harness the best European research and synergise the strengths by working together in a shared strategy for research.
European Clinical Expertise
The scarcity of qualified clinicians knowledgeable about ME means this must be a priority to address. EMECC is already building some fundamental agreement on standards and will develop more influence to overcome ignorance and lack of education about ME.
European Patient Advocacy
Patients need to be made aware of the possibilities of EMERG and EMECC and have a powerful voice which can be heard by researchers, clinicians, polticians and the media and public. EMEA provides this with national campaigning linked to a strategy of collaborative advocacy.
Alone, we can do so little; together we can do so much.